Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06717698 · ClinicalTrials.gov registry record · Phase 2

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

A Phase 2 study of Chronic Kidney Disease, sponsored by Novo Nordisk A/S.

Recruiting
Registry status
Phase 2
Development phase
465
Enrollment target
20
Study locations

NCT06717698 is a Phase 2 study of Chronic Kidney Disease that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 465 participants, below the 3,202-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06717698, a Phase 2 study of Chronic Kidney Disease, is actively recruiting participants, sponsored by Novo Nordisk A/S.

RECRUITING
Registry status
Phase 2
Development phase
465 participants
Enrollment target
20
Study locations

Study Summary

The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study will last for up to 43 weeks.

Conditions Studied

Chronic Kidney Disease

Interventions

  • DRUG Placebo
  • DRUG Semaglutide
  • DRUG NNC0519-0130

Study Locations (20)

Florida

  • Northeast Research Institute - Fleming Island
  • Encore Medical Research LLC - Hollywood
  • Northeast Research Institute - Saint Augustine
  • Clinical Research of Cent FL - Winter Haven

Texas

  • Davita Clinical Research - El Paso
  • Clinical Advancement Center - San Antonio
  • Tekton Research - San Antonio

California

  • N America Res Inst - San Dimas - San Dimas
  • NorCal Endocrinology and Internal Medicine - San Ramon

North Carolina

  • Carteret Medical Group - Morehead City
  • Brookview Hills Research Associates, LLC - Winston-Salem

Buenos Aires

  • Centro Médico CIMEL - Lanús Este
  • Renalida - Mar del Plata

Colorado

  • Rocky Mount Reg VA Med-DN - Aurora

Illinois

  • Endeavor Health - Skokie

Indiana

  • Velocity Clin. Res Valparaiso - Valparaiso

Trial Details

FieldValue
Enrollment Target 465 participants
Start Date 2024-12-02
Est. Completion 2026-09-17
Phase Phase 2

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06717698

The ClinicalTrials.gov registry entry for NCT06717698 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 465 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,202-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (85% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06717698 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Texas, California.

Frequently Asked Questions

What is clinical trial NCT06717698 about?

NCT06717698 is a clinical study titled "A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease". The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NN...

What is the current status of trial NCT06717698?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 465 participants. The study started on 2024-12-02. Estimated completion is 2026-09-17.

What conditions does trial NCT06717698 study?

This clinical trial studies the following conditions: Chronic Kidney Disease.

What interventions are being tested in trial NCT06717698?

The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), NNC0519-0130 (DRUG).

Who is sponsoring clinical trial NCT06717698?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06717698 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Kidney Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.